Corium International (NASDAQ:CORI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
A number of other equities analysts have also weighed in on the company. ValuEngine upgraded Corium International from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. BidaskClub upgraded Corium International from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. HC Wainwright set a $14.00 target price on Corium International and gave the stock a “buy” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 target price on shares of Corium International in a research note on Tuesday, March 27th. Finally, Needham & Company LLC decreased their target price on Corium International from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, December 26th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $13.00.
NASDAQ:CORI opened at $10.46 on Thursday. The company has a debt-to-equity ratio of 5.91, a quick ratio of 1.34 and a current ratio of 1.40. Corium International has a 52-week low of $4.04 and a 52-week high of $13.93. The firm has a market cap of $384.72, a P/E ratio of -6.38 and a beta of 1.59.
Corium International (NASDAQ:CORI) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. The company had revenue of $9.32 million for the quarter, compared to analyst estimates of $7.48 million. research analysts forecast that Corium International will post -1.47 earnings per share for the current year.
In other news, major shareholder Perceptive Advisors Llc acquired 50,350 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was purchased at an average cost of $11.83 per share, for a total transaction of $595,640.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive acquired 510,000 shares of the business’s stock in a transaction dated Thursday, January 18th. The stock was purchased at an average price of $12.54 per share, with a total value of $6,395,400.00. The disclosure for this purchase can be found here. 30.80% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in shares of Corium International by 14.0% in the 4th quarter. Renaissance Technologies LLC now owns 96,900 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 11,900 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Corium International by 6.0% in the 4th quarter. Geode Capital Management LLC now owns 223,536 shares of the biopharmaceutical company’s stock worth $2,147,000 after purchasing an additional 12,745 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Corium International in the 4th quarter worth about $123,000. Schwab Charles Investment Management Inc. boosted its holdings in shares of Corium International by 47.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 15,909 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Corium International by 126.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 18,416 shares in the last quarter. Hedge funds and other institutional investors own 88.58% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/07/zacks-investment-research-downgrades-corium-international-cori-to-hold.html.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.